Business Description
Ascelia Pharma AB
ISIN : SE0010573113
Compare
Compare
Traded in other countries / regions
ACE.Sweden7ZA.GermanyACEs.UK IPO Date
2019-03-13Description
Ascelia Pharma AB is an oncology-dedicated drug development company located in Malmo Sweden focused on orphan oncology It develops and commercializes novel drugs that address unmet medical needs and have a clear development and market pathway The company has two drug candidates Orviglance and Oncoral in clinical development.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 20.62 | |||||
| Equity-to-Asset | 0.85 | |||||
| Debt-to-Equity | 0.01 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 1/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 5 | |||||
| 3-Year EPS without NRI Growth Rate | 5.1 | |||||
| 3-Year FCF Growth Rate | -4.8 | |||||
| 3-Year Book Growth Rate | -35.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 38.46 | |||||
| 9-Day RSI | 44.67 | |||||
| 14-Day RSI | 48.7 | |||||
| 6-1 Month Momentum % | 226.6 | |||||
| 12-1 Month Momentum % | -35.23 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | |||||
| Quick Ratio | 2.3 | |||||
| Cash Ratio | 1.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -6.2 | |||||
| Shareholder Yield % | -0.16 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -92.6 | |||||
| ROA % | -74.69 | |||||
| ROIC % | -140.86 | |||||
| ROC (Joel Greenblatt) % | -8375.9 | |||||
| ROCE % | -92.52 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 4.8 | |||||
| Price-to-Tangible-Book | 20.75 | |||||
| EV-to-EBIT | -3.07 | |||||
| EV-to-Forward-EBIT | -3.27 | |||||
| EV-to-EBITDA | -3.07 | |||||
| EV-to-Forward-EBITDA | -3.27 | |||||
| EV-to-FCF | -2.81 | |||||
| Price-to-Net-Current-Asset-Value | 22.04 | |||||
| Price-to-Net-Cash | 39.19 | |||||
| Earnings Yield (Greenblatt) % | -32.56 | |||||
| FCF Yield % | -35.51 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Ascelia Pharma AB Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil kr) | |||
| EPS (TTM) (kr) | -3.2 | ||
| Beta | 1.1 | ||
| Volatility % | 176.29 | ||
| 14-Day RSI | 48.7 | ||
| 14-Day ATR (kr) | 1.148669 | ||
| 20-Day SMA (kr) | 11.133 | ||
| 12-1 Month Momentum % | -35.23 | ||
| 52-Week Range (kr) | 2.62 - 17.5 | ||
| Shares Outstanding (Mil) | 33.76 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Ascelia Pharma AB Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Ascelia Pharma AB Stock Events
| Event | Date | Price(kr) | ||
|---|---|---|---|---|
| No Event Data | ||||
Ascelia Pharma AB Frequently Asked Questions
What is Ascelia Pharma AB(OSTO:ACE)'s stock price today?
The current price of OSTO:ACE is kr10.58. The 52 week high of OSTO:ACE is kr17.50 and 52 week low is kr2.62.
When is next earnings date of Ascelia Pharma AB(OSTO:ACE)?
The next earnings date of Ascelia Pharma AB(OSTO:ACE) is 2024-05-16.
Does Ascelia Pharma AB(OSTO:ACE) pay dividends? If so, how much?
Ascelia Pharma AB(OSTO:ACE) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers